Introduction#
ImmuPharma PLC, a biopharmaceutical company, has announced the start of its IND-enabling activities for Kapiglucagon, a drug aimed at treating Type 1 diabetes. This marks a significant step in the development of this new treatment.
Collaboration with Experts#
To support this initiative, ImmuPharma has partnered with tranScrip Limited, a pharmaceutical consultancy. This collaboration will help in formulating a regulatory strategy and preparing for a pre-IND meeting with the U.S. Food and Drug Administration (FDA). The pre-IND meeting is a crucial step where the company will discuss its plans and gather feedback from the FDA on the necessary steps to move forward.
Regulatory Strategy#
ImmuPharma is considering a 505(b)(2) regulatory pathway in the United States. This approach allows the company to use existing data on native glucagon, which is the natural hormone that Kapiglucagon is based on. This could potentially streamline the approval process, but it still requires confirmation from the FDA.
Benefits of Kapiglucagon#
Kapiglucagon aims to overcome some limitations of native glucagon, particularly in terms of solubility and stability. The drug could be beneficial in dual-hormone artificial pancreas systems, which are designed to help manage blood sugar levels in people with diabetes. The next key step for ImmuPharma will be the pre-IND meeting with the FDA, where they will discuss the necessary Chemistry, Manufacturing, and Controls, as well as preclinical and clinical programs needed for the drug's development.
Future Steps#
Dr. Sébastien Goudreau, the Chief Scientific Officer of ImmuPharma, emphasized that starting these IND-enabling activities is a significant advancement for Kapiglucagon. The company is also supported by a recently approved funding initiative, which will help propel the development of this promising treatment over the next two years.